Lexicon Pharmaceuticals (LXRX) Debt to Equity (2023 - 2025)
Lexicon Pharmaceuticals (LXRX) has disclosed Debt to Equity for 6 consecutive years, with $0.5 as the latest value for Q4 2025.
- On a quarterly basis, Debt to Equity fell 26.93% to $0.5 in Q4 2025 year-over-year; TTM through Dec 2025 was $0.5, a 26.93% decrease, with the full-year FY2025 number at $0.5, down 26.93% from a year prior.
- Debt to Equity was $0.5 for Q4 2025 at Lexicon Pharmaceuticals, up from $0.47 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $1.07 in Q4 2023 to a low of $0.35 in Q1 2024.
- A 3-year average of $0.59 and a median of $0.54 in 2023 define the central range for Debt to Equity.
- Peak YoY movement for Debt to Equity: plummeted 37.66% in 2024, then surged 136.67% in 2025.
- Lexicon Pharmaceuticals' Debt to Equity stood at $1.07 in 2023, then tumbled by 35.7% to $0.69 in 2024, then fell by 26.93% to $0.5 in 2025.
- Per Business Quant, the three most recent readings for LXRX's Debt to Equity are $0.5 (Q4 2025), $0.47 (Q3 2025), and $0.43 (Q2 2025).